Navigation Links
STAAR Surgical To Present At The Benchmark And Jefferies Investor Conferences
Date:5/29/2012

MONROVIA, Calif., May 29, 2012 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it  will participate in two upcoming investor conferences to review the Company's recent financial results and current business developments with investors and interested parties.

The Benchmark Company One-on-One Investor Conference will be held on Thursday, May 31, 2012 at the Pfister Hotel in Milwaukee, Wisconsin.  Barry G. Caldwell, President and CEO, and Deborah Andrews, CFO, will meet with interested investors in a series of one-on-one meetings.

This Benchmark Company Investor Conference does not provide for companies to webcast the event; however, a copy of the Company's Conference presentation will be available at the Company's website, www.staar.com, under Investor Information. Investors planning to attend the conference should contact their Benchmark representative to arrange a meeting.

The Company will also present at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 3:00 p.m. ET.  Barry G. Caldwell, President and CEO, Deborah Andrews, CFO, and Sam Gesten, General Counsel, will be attending the conference.

STAAR will offer a live video webcast of its presentation on the Company's website, www.staar.com, under Investor Information. An archived replay of the presentation will be available for 30 days, also at www.staar.com.

About STAAR SurgicalSTAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye.  All of these lenses are foldable, which permits the surgeon to insert them through a small incision.  STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL."  A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL."  Over 300,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com.
STAAR has approximately 300 full time employees and markets lenses in approximately 50 countries.  Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.  For more information, please visit the Company's website at www.staar.com or call 626-303-7902. 

Collamer® is the registered trademark for STAAR's proprietary biocompatible collagen copolymer lens material.  CONTACT: Investors

Media EVC Group

EVC GroupDouglas Sherk, 415-652-9100

Chris GaleJenifer Kirtland, 415-568-9349

646-201-5431


'/>"/>

SOURCE STAAR Surgical Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
4. STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS
5. STAAR Surgical Reports Continued Double Digit Core Revenue Growth
6. STAAR Surgicals Visian® ICL Surpasses 200,000 Implants
7. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
8. STAAR Surgical Enters Into Distribution Agreement With Ellex in Australia
9. STAAR Surgical Launches Second Phase of Visian ICL Direct-to-Consumer Advertising Campaign
10. STAAR Surgicals nanoFLEX™ Collamer® IOL Receives CE Mark Approval
11. STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, announced today that ... agreement with Morgan Stanley & Co. LLC to repurchase ... part of the Company,s previously authorized program to repurchase ... --> --> ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its fiscal ... --> --> GAAP results: Revenue ... up $5.1 million or 4.1% from the third quarter ... the fourth quarter of 2014. Revenue for the year ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute ... at the tips of your toes. Foot massage, whether administered by a professional masseuse ... and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... Grants Pass, OR (PRWEB) , ... February 05, 2016 , ... ... though, with modern technology, such water may be safer than regular municipal or well ... water advocate and radio host Sharon Kleyne, could go a long way toward increasing ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
Breaking Medicine News(10 mins):